Literature DB >> 33146875

Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.

Gillian A Beauchamp1,2, Lexis T Laubach3, Samantha B Esposito3, Ali Yazdanyar3, Paige Roth3, Priyanka Lauber3, Jamie Allen3, Nathan Boateng4, Samantha Shaak5, David B Burmeister3.   

Abstract

INTRODUCTION: Implementing a hospital medication for addiction treatment (MAT) and a linkage program can improve care for patients with substance use disorder (SUD); however, lack of hospital funding and brick and mortar SUD resources are potential barriers to feasibility.
METHODS: This study assesses the feasibility of implementation of a SUD linkage program. Components of the program include a county-funded hospital opioid support team (HOST), a hospital-employed addiction recovery specialist (ARS), and a medical toxicology MAT induction service and maintenance program. Data for linkage by HOST, ARS, and MAT program were tracked from July 2018 to December 2019.
RESULTS: From July 2018 through December 2019, 1834 patients were linked to treatment: 1536 by HOST and 298 by the ARS. The most common disposition categories for patients linked by HOST were 16.73% to medically monitored detoxification, 9.38% to intensive outpatient, and 8.59% to short-term residential treatment. Among patients linked by the ARS, 65.66% were linked to outpatient treatment and 9.43% were linked directly to inpatient treatment. A total of 223 patients managed by the ARS were started on MAT by medical toxicology and linked to outpatient MAT clinic: 72.68% on buprenorphine/naloxone, 24.59% on naltrexone, 1.09% buprenorphine, and 0.55% acamprosate.
CONCLUSION: Implementing a MAT and linkage program in the ED and hospital setting was feasible. Leveraging medical toxicology expertise as well as community and funding partnerships was crucial to successful implementation.

Entities:  

Keywords:  Emergency medicine; Medical toxicology; Medication for addiction treatment; Substance use disorder

Mesh:

Substances:

Year:  2020        PMID: 33146875      PMCID: PMC8017051          DOI: 10.1007/s13181-020-00813-4

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  25 in total

1.  Office-based treatment for opioid dependence: reaching new patient populations.

Authors:  D A Fiellin; R A Rosenheck; T R Kosten
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

Review 2.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

3.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

4.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

5.  The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment.

Authors:  Hayley Pinto; Vivienne Maskrey; Louise Swift; Daphne Rumball; Ajay Wagle; Richard Holland
Journal:  J Subst Abuse Treat       Date:  2010-12

Review 6.  Prevention, screening, and treatment for heavy drinking and alcohol use disorder.

Authors:  Justin Knox; Deborah S Hasin; Farren R R Larson; Henry R Kranzler
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

7.  Implementation of the Provision of the Comprehensive Addiction and Recovery Act of 2016 Relating to the Dispensing of Narcotic Drugs for Opioid Use Disorder. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2018-01-23

8.  Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder.

Authors:  Honora Englander; Melissa Weimer; Rachel Solotaroff; Christina Nicolaidis; Benjamin Chan; Christine Velez; Alison Noice; Tim Hartnett; Ed Blackburn; Pen Barnes; P. Todd Korthuis
Journal:  J Hosp Med       Date:  2017-05       Impact factor: 2.960

Review 9.  The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Authors:  Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2016-03

10.  Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program.

Authors:  Kevin A Kaucher; Emily H Caruso; Gannon Sungar; Lisa Gawenus; Katherine Hurlbut; Dayan Colon Sanchez; Kerry Broderick
Journal:  Am J Emerg Med       Date:  2019-07-30       Impact factor: 2.469

View more
  2 in total

1.  Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder.

Authors:  Margaret Lowenstein; Jeanmarie Perrone; Ruiying A Xiong; Christopher K Snider; Nicole O'Donnell; Davis Hermann; Roy Rosin; Julie Dees; Rachel McFadden; Utsha Khatri; Zachary F Meisel; Nandita Mitra; M Kit Delgado
Journal:  Ann Emerg Med       Date:  2021-12-23       Impact factor: 5.721

Review 2.  A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews.

Authors:  Honora Englander; Amy Jones; Noa Krawczyk; Alisa Patten; Timothy Roberts; P Todd Korthuis; Jennifer McNeely
Journal:  J Gen Intern Med       Date:  2022-05-09       Impact factor: 6.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.